- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
Introduction: A brief overview of adipose tissue metabolism
Ernst R Lengyel
Univ. of Chicago, Chicago, IL, United States
- Free
- slides video
- audio + slides
- All slides included
Paracrine role of mammary adipocytes in breast cancer progression and drug resistance
Catherine Muller
Institut de Pharmacologie et de Biologie Structurale, Toulouse, France
- Free
- audio + slides
- Some slides withheld
The contribution of adipose fatty acid binding protein in cancer progression
Bing Li
Univ. of Louisville School of Medicine, Louisville, KY, United States
- Free
- Coming soon
- Some slides withheld
Adipose stromal cell role in EMT and chemoresistance
Mikhail Kolonin
The University of Texas Health Science Center at Houston, Houston, TX, United States
- Free
- slides video
- audio + slides
- All slides included
Cancer and obesity: Stromal contributions of adipocytes to cancer progression
Philipp E. Scherer
UT Southwestern Medical Ctr., Dallas, TX, United States
- Free
- slides video
- audio + slides
- All slides included
Chairperson
Nicholas Mitsiades
Baylor College of Medicine,
- Free
- audio + slides
- Some slides withheld
Clinical relevance of comprehensive genomic analysis in patients with advanced-stage neuroendocrine neoplasms: Results from the MASTER trial of the German Cancer Consortium
Simon Kreutzfeldt
National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany
- Permission not
granted for presentation
p97/VCP: A novel interactor of the sodium iodide symporter, which can be pharmacologically targeted to increase radioiodine uptake in thyroid and breast cancer cells
Alice Fletcher
University of Birmingham, Birmingham, United Kingdom
- Free
- slides video
- audio + slides
- All slides included
Novel clinical targets revealed by kinome reprogramming in mutant ESR1 metastatic breast cancer
Derek Dustin
Baylor College of Medicine, Houston, TX, United States
- Permission not
granted for presentation
Preclinical anticancer activity of LSZ102, a novel oral selective estrogen receptor degrader targeting wild-type and mutant ER
Tinya J Abrams
Novartis, Cambridge, MA, United States
- Free
- slides video
- audio + slides
- All slides included
FOXA1 chromatin binding is regulated by LSD1-mediated methylation in prostate cancer cells
Changmeng Cai
University of Massachusetts Boston, Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
The androgen receptor antagonist darolutamide shows strong antitumor efficacy in patient- and cell line-derived xenograft prostate cancer models
Bernard Haendler
Bayer AG, Berlin, Germany
- Free
- slides video
- audio + slides
- All slides included
PDX models of ER+ endocrine-resistant metastatic breast cancer identify Polo-like kinase 1 (PLK1) as a therapeutic target
Elisabetta Marangoni
Inst. Curie, Paris, France
- Permission not
granted for presentation
Epigenomic approaches to identify transcriptional dependencies in prostate cancer
Qianben Wang
Duke University, Durham, NC, United States
- Free
- slides video
- audio + slides
- All slides included
Cistrome mining for new therapeutic targets in hormone-dependent cancers
Myles A Brown
Dana-Farber Cancer Inst., Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Long-range epigenetic control of estrogen-responsive transcription
Tim Hui-Ming Huang
UT Health Science Ctr. at San Antonio, San Antonio, TX, United States
- Free
- slides video
- audio + slides
- All slides included
Reducing age associated radiation and chemotherapy normal tissue injury
Bryan G Allen
Univ. of Iowa Hospitals and Clinics, Iowa City, IA, United States
- Free
- slides video
- audio + slides
- All slides included
Non-mutational effects of radiation on ageing
Ken Raj
Public Health England, London, United Kingdom
- Free
- audio + slides
- Some slides withheld
Rescue of cognitive function following fractionated brain irradiation in a novel preclinical glioma model
Susanna Rosi
University of California, San Francisco, San Francisco, CA, United States
- Free
- Coming soon
- Some slides withheld
Overview of thyroid cancer: Epidemiology to state-of art standard of care
Steven I. Sherman
UT MD Anderson Cancer Center, Houston, TX, United States
- Free
- slides video
- audio + slides
- All slides included
Cancer genomics: Well to poorly differentiated thyroid carcinoma
James A Fagin
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
Discovering targeted therapies of thyroid cancer using drosophila models
Ross L Cagan
Mount Sinai School of Medicine, New York, NY, United States
- Free
- audio + slides
- Some slides withheld
BRAF-targetedtherapy and mechanisms of resistance in thyroid cancer clinical trials
Manisha H Shah
Ohio State Univ. Comp. Cancer Ctr., Columbus, OH, United States
- Free
- slides video
- audio + slides
- All slides included
Emerging novel RET-Targeted therapy in thyroid cancer
Lori J Wirth
Massachusetts General Hospital, Boston, MA, United States
- Free
- audio only
- Audio only
SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust antitumor efficacy and limited cross-resistance in ER+ breast cancer
Maysoun Shomali
Sanofi, Cambridge, MA, United States